Epstein-Barr virus (EBV) establishes a lifelong latent infection in humans and is associated with several lymphoid and epithelial cancers. In nasopharyngeal carcinoma (NPC), EBV revealed several viral proteins but increased levels of Bam-HI A right to the transcript (Barts) RNA, including viral microRNAs and long non-coding RNA (lncRNAs). BART lncRNAs localize in the nucleus of EBV-infected cells and knockdown of BART lncRNAs significantly affect the expression of genes associated with cell adhesion, oxidoreductase activity, inflammation, and immunity.
Specifically, downregulation of IKAROS zinc finger family of 3 (IKZF3 / Aeolus), which plays a role in lymphocyte development and attachment of cells, occurs in cells following C666-1 NPC lncRNA BART-knockdown. Since the expression of Aeolus is usually limited to cells of lymphoid and rarely observed in the epithelial cells, induction of Aeolus by lncRNA BART BART confirmed by major express lncRNA isoforms, RPMS1, in EBV-positive cells and negative.
BART lncRNA associated with CBP / p300 complex and RNA polymerase II (Pol II) in the nucleus, suggesting that the BART lncRNAs can mediate epigenetic regulation of gene expression through interactions with chromatin remodeling machinery. This assumption is further supported by evidence that the BART lncRNA seemed to stall Pol II promoter region and can arrange IFNB1 and CXCL8 expression by inhibiting transcription by Pol II at the NPC.
We hypothesize that EBV BART lncRNA modulated expression host gene expression and sustain EBV latency by interrupting the process of histone methylation and acetylation. aberrant expression of genes affected host mediated by BART lncRNA can cause immune evasion, growth, and metastasis of NPC.
Epstein-Barr Virus BART Long Non-coding RNAs Function as Epigenetic Modulators in Nasopharyngeal Carcinoma.
[The effect of increasing the intensity of chemotherapy on the prognosis of acute lymphoblastic leukemia in children with IKZF1 deletion].
To study the clinical features of acute lymphoblastic leukemia (ALL) in children with IKAROS family of zinc finger 1 (IKZF1) deletion, and to observe the effect of increasing the intensity of chemotherapy in this prognosis disease.A number of 278 children diagnosed with ALL between December 2015 and February 2018 were systematically treated in accordance with the 2008-ALL Leukemia Group protocol Chinese Children (CCLG-ALL 2008).
The patients were divided into groups IKZF1-cleared and control groups according to the presence or absence of IKZF1. IKZF1-erased group treated with the regimen for high-risk groups (SDM) in CCLG-ALL protocol of 2008, while the control group receiving different intensities of chemotherapy according to clinical risk classification. Clinical features and rate of event-free survival (EFS) compared between the two groups.
RESULTS A total of 24 (8.6%) cases of 278 children were found to have a large deletion of exon gene IKZF1. IKZF1-deleted group have significantly higher proportion of cases with white blood cell counting ≥50 × 109 / L at initial diagnosis, BCR-ABL1 fusion gene positive, minimal residual disease ≥10% on the 15th of remission induction treatment, minimal residual disease- high-risk and high-risk clinical risk classification compared with the control group (P <0.05).
Description: A sandwich quantitative ELISA assay kit for detection of Human Tachykinin Receptor 1 (TACR1) in samples from tissue homogenates, cell lysates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Human Tachykinin Receptor 1 (TACR1) in samples from tissue homogenates, cell lysates or other biological fluids.
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Tachykinin Receptor 1 (TACR1) in Tissue homogenates, cell lysates and other biological fluids.
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Tachykinin Receptor 1 (TACR1) in Tissue homogenates, cell lysates and other biological fluids.
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Tachykinin Receptor 1 (TACR1) in Tissue homogenates, cell lysates and other biological fluids.
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Tachykinin Receptor 1 (TACR1) in Tissue homogenates, cell lysates and other biological fluids.
Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Human Tachykinin Receptor 1 (TACR1) in samples from Tissue homogenates, cell lysates and other biological fluids with no significant corss-reactivity with analogues from other species.
Description: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Rat TACR1. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Rat TACR1. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Rat TACR1, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Rat TACR1 in the samples is then determined by comparing the OD of the samples to the standard curve.
Description: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Rat TACR1. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Rat TACR1. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Rat TACR1, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Rat TACR1 in the samples is then determined by comparing the OD of the samples to the standard curve.
Description: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Human TACR1. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Human TACR1. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Human TACR1, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Human TACR1 in the samples is then determined by comparing the OD of the samples to the standard curve.
Description: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Human TACR1. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Human TACR1. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Human TACR1, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Human TACR1 in the samples is then determined by comparing the OD of the samples to the standard curve.
Description: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Mouse TACR1. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Mouse TACR1. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Mouse TACR1, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Mouse TACR1 in the samples is then determined by comparing the OD of the samples to the standard curve.
Description: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Mouse TACR1. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Mouse TACR1. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Mouse TACR1, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Mouse TACR1 in the samples is then determined by comparing the OD of the samples to the standard curve.
Description: A sandwich ELISA kit for detection of Tachykinin Receptor 1 from Human in samples from blood, serum, plasma, cell culture fluid and other biological fluids.
Description: A competitive ELISA for quantitative measurement of Canine Tachykinin Receptor 3 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Canine Tachykinin Receptor 3 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Canine Tachykinin Receptor 3 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Rat Tachykinin Receptor 3 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Rat Tachykinin Receptor 3 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
×
3-year EFS rates (76% ± 10%) in the group-deleted IKZF1 lower than in the control group (84% ± 4%), but with no significant difference between the two groups (P = 0.282). An estimated 3 year rate of EFS in a group IKZF1-cleared non-HR (actually treated with chemotherapy regimens for HR in CCLG-ALL protocol 2008) was 82% ± 12%, lower than that in the control-which is a group of non-HR (86 % ± 5%), but no significant difference (P = 0.436).
